Ckd Bio Market Cap ($45.84 Million)
Market Cap & Net Worth: Ckd Bio (063160)
Ckd Bio market cap. Ckd Bio (KO:063160) has a market capitalization of $45.84 Million (₩67.64 Billion) as of November 3, 2026. Listed on the KO stock exchange, this Korea-based company holds position #22053 globally and #1365 in its home market, demonstrating a -3.29% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ckd Bio's stock price ₩12330.00 by its total outstanding shares 5485959 (5.49 Million). Also see Ckd Bio cash flow conversion for how efficiently the company converts equity into cash flow.
Ckd Bio Market Cap History (2015–2026)
Ckd Bio market cap history from 2015 to 2026. Data shows change from $91.76 Million to $45.84 Million (-3.29% CAGR). Check 063160 stock price for real-time trading data and today's change.
Ckd Bio Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ckd Bio's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Ckd Bio to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
Ckd Bio's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $79.67 Million | $113.01 Billion | $9.43 Billion | 0.00x | 0.01x |
| 2017 | $73.63 Million | $118.19 Billion | $8.02 Billion | 0.00x | 0.01x |
| 2018 | $72.28 Million | $124.51 Billion | $7.96 Billion | 0.00x | 0.01x |
| 2019 | $108.66 Million | $137.18 Billion | $12.26 Billion | 0.00x | 0.01x |
| 2020 | $295.10 Million | $124.60 Billion | $6.21 Billion | 0.00x | 0.05x |
| 2021 | $154.76 Million | $142.24 Billion | -$6.58 Billion | 0.00x | N/A |
| 2022 | $88.48 Million | $156.04 Billion | -$16.70 Billion | 0.00x | N/A |
| 2023 | $88.67 Million | $160.35 Billion | -$24.19 Billion | 0.00x | N/A |
| 2024 | $81.79 Million | $171.76 Billion | $8.70 Billion | 0.00x | 0.01x |
| 2025 | $75.66 Million | $160.07 Billion | -$2.89 Billion | 0.00x | N/A |
Competitor Companies of 063160 by Market Capitalization
Companies near Ckd Bio in the global market cap rankings as of November 3, 2026. Also see total assets of Ckd Bio for a full breakdown of the balance sheet.
Key companies related to Ckd Bio by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.59 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Ckd Bio (2015–2026)
Market capitalization of Ckd Bio from 2015 to today. Between 2015 and today, Ckd Bio's market cap moved from $91.76 Million to $ 45.84 Million, with a yearly change of -3.29%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩45.84 Million | -39.41% |
| 2025 | ₩75.66 Million | -7.50% |
| 2024 | ₩81.79 Million | -7.76% |
| 2023 | ₩88.67 Million | +0.21% |
| 2022 | ₩88.48 Million | -42.83% |
| 2021 | ₩154.76 Million | -47.56% |
| 2020 | ₩295.10 Million | +171.58% |
| 2019 | ₩108.66 Million | +50.33% |
| 2018 | ₩72.28 Million | -1.83% |
| 2017 | ₩73.63 Million | -7.58% |
| 2016 | ₩79.67 Million | -13.18% |
| 2015 | ₩91.76 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 2nd, 2026 the market cap of Ckd Bio was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $45.84 Million USD |
| MoneyControl | $45.84 Million USD |
| MarketWatch | $45.84 Million USD |
| marketcap.company | $45.84 Million USD |
| Reuters | $45.84 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ckd Bio
CKD Bio Corp. engages in the manufacturing and sale of pharmaceutical products in South Korea, Europe, Asia, the Middle East, and internationally. The company is also involved in real estate leasing and related ancillary; bio, cosmetics, and health functional food; property management; advertising communication; consulting, construction, and maintenance of corporate IT systems business. It also e… Read more